---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-326406"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:28:17.731469+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa names first development candidate MRT-2359 targeting GSPT1; Q3 net loss $19.8M

## Summary
- Selected MRT-2359 as first development candidate; initiated IND-enabling studies for mid-2022 IND submission.
- Q3 2021 net loss $19.8M vs $6.6M in Q3 2020; R&D expenses $15.1M up from $5.5M.
- Cash and equivalents $367M as of Sept 30, 2021, expected to fund operations into late 2024.
- Presented preclinical data on GSPT1 degraders for Myc-driven cancers at AACR-NCI-EORTC.
- NEK7 program in lead optimization; expect at least one more program to enter lead optimization in 2021.

## SEC filing metadata
- accession: 0001193125-21-326406
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312521326406/0001193125-21-326406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312521326406/d244737d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-326406
- JSON: https://secwatch.observer/filing/0001193125-21-326406.json
- Plain text: https://secwatch.observer/filing/0001193125-21-326406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.